This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
QR Pharma, Inc.
Drug Names(s): Posiphen
Description: Posiphen is the positive isomer to Phenserine. It targets the mRNA of a number of proteins that are overexpressed in several neurological disorders such as Alzheimer's disease, Parkinson's disease and Down syndrome. It reduces the rate of synthesis of amyloid precursor protein (APP) in cell cultures, normal, transgenic and trisomic mice as well as in humans. Posiphen also inhibits the synthesis of tau and alpha-synuclein in mice and humans. These neurotoxic aggregating proteins induce dysfunction, neuroinflammation and lead to cognitive impairment and neurodegeneration.
Axonyx and TorreyPines
In June 2006, Axonyx and TorreyPines Therapeutics announced that they entered into a definitive merger agreement. This agreement was finalized in October 2006.
Cenomed and TorreyPines - Chemical Defense and Counterterrorism Defense
In October 2008, Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, and TorreyPines Therapeutics announced that they entered into an exclusive licensing agreement whereby Cenomed acquired from TorreyPines Therapeutics the worldwide development rights held by TorreyPines to three compounds: phenserine, Posiphen and bisnorcymcerine, for chemical defense and counterterrorism defense. Cenomed intends to develop these compounds for potential use in preventing toxicity following exposure to chemical organophosphorus nerve agents, including the chemical warfare agents sarin, soman, tabun and VX. Pursuant to the terms of the agreement, TorreyPines will receive potential future milestone and...See full deal structure in Biomedtracker
Partners: Raptor Pharmaceutical Corp. Cenomed BioSciences, LLC
Scrip From LSD To GD To PD
Additional information available to subscribers only: